Toronto, Ontario / TheNewswire  / December 15 2016 – Eyecarrot Innovations Corp (TSX-V: EYC) is pleased to announce that it has appointed Dr. Sam Mithani to the role of Chief Technology Officer and Director effective immediately. Over the past 12 months, he has played a key role in developing and extending Eyecarrot’s product and technology strategy. Dr. Mithani most recently served as the CTO of Made with Magnolia Inc. where he focused on iOS application architecture and development. He brings over 2 decades of experience managing large multi-disciplinary teams and has extensive knowledge of scalable infrastructure and software engineering.

“Dr. Mithani brings a wide range of technical experience to Eyecarrot and he fills a very important role in the senior leadership team. His guidance and vision has been instrumental in the development and advancement of our BinoviTM platform and his drive for innovation aligns well with Eyecarrot’s core values. I am thrilled to have him join our team,” commented Adam Cegielski, CEO of Eyecarrot

“I can’t think of a more exciting time to take on a formal leadership role at Eyecarrot. This is an extraordinary opportunity to leverage my background and experience in science and technology and to apply it to real world solutions in the digital healthcare space. I look forward to building on the strong culture of collaboration and innovation at Eyecarrot,” says Dr. Sam Mithani.

Dr. Sam Mithani graduated from University of Waterloo with a Ph.D. in Organic Chemistry and entered the pharmaceutical industry. Over the next eleven years he took on successively senior roles, including VP, Technical Services in the Fine Chemical Division at Apotex, gaining experience leading a large multi-disciplinary, multi-site team in a regulated environment, encompassing analytical services, quality control, instrument integration and validation, IT/IS infrastructure, security systems, as well as enterprise software engineering. Dr. Mithani left Apotex to follow his passion for mac and iOS development at Indusblue where he took a leading role in the development of a number of award-winning IOS apps. Over the next two years, Dr. Mithani led Freshbooks’ Android initiative and Triggerfox’s iOS team, prior to their acquisition by Influitive. More recently, as the CTO of a new startup with partners from Indusblue, he established a SaaS magazine platform and contract development services, specializing in Xamarin, Android and iOS development.

About Eyecarrot

Eyecarrot’s goal is to power a global, data-driven, expert therapeutic network to transform how human Oculomotor Sensory performance is diagnosed, exercised and enhanced. The company is building BinoviTM, a universal, collaborative care platform that integrates software, hardware, data and the expert knowledge of vision care professionals to help patients on a global scale. Learn more at www.eyecarrot.com

On behalf of the Board of Directors

Adam Cegielski

President | CEO

Telephone: 1.855.416.7158 - 416.943.6271

Forward looking information

Certain statements contained in this news release constitute "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company's financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company's financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company's continuous disclosure filings filed under the Company's profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.